Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-7: nemvaleukin alfa with pembrolizumab versus investigator's choice chemotherapy in platinum-resistant ovarian cancer
NL-OMON51689Phase 3Withdrawn
- Sponsor
- Alkermes
- Start
- Jun 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nemvaleukin alfa, pembrolizumab, doxorubicin, paclitaxel, topotecan and 1 more in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Alkermes. Primary endpoint: Progression-free survival. Planned start Jun 2022; status: withdrawn.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON51689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51689.